WO2023144665 - MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS
National phase entry:
Publication Number
WO/2023/144665
Publication Date
03.08.2023
International Application No.
PCT/IB2023/050457
International Filing Date
19.01.2023
Title **
[English]
MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINS
[French]
PROTÉINES DE CYTOMÉGALOVIRUS HUMAIN MODIFIÉES
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors
BIANCUCCI, Marco
WAHOME, Newton Muchugu
Priority Data
63/304,193
28.01.2022
US
63/350,123
08.06.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2902 | |
| EPO | Filing, Examination, Granting | 18508 | |
| Japan | Filing, Examination, Granting | 2740 | |
| South Korea | Filing, Examination, Granting | 3179 | |
| USA | Filing, Examination, Granting | 10940 |
Total:
38,269
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Modified HCMV gB proteins in a pre-fusion conformation, compositions comprising such proteins, and uses thereof.[French]
L'invention concerne des protéines gB de HCMV modifiées dans une conformation de pré-fusion, des compositions comprenant de telles protéines, et leurs utilisations.